PE20030865A1 - Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c - Google Patents
Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis cInfo
- Publication number
- PE20030865A1 PE20030865A1 PE2003000135A PE2003000135A PE20030865A1 PE 20030865 A1 PE20030865 A1 PE 20030865A1 PE 2003000135 A PE2003000135 A PE 2003000135A PE 2003000135 A PE2003000135 A PE 2003000135A PE 20030865 A1 PE20030865 A1 PE 20030865A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- cycloalkyl
- hepatitis
- hilo
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA INHHIBIR EL VIRUS DE LA HEPATITIS C CON UNA BIODISPONIBILIDAD MEJORADA QUE COMPRENDE a)DE 1% A 50% DE COMPUESTOS MACROCICLICOS INHIBIDORES DE PROTEASA NS3 VIRAL DE FORMULA I, DONDE: R1 ES H, HALO, ALQUILO, CICLOALQUILO, HALOALQUILO, ALCOXI, CICLOALCOXI, ENTRE OTROS; R2 ES H, HALO, ALQUILO, CICLOALQUILO, ENTRE OTROS; R3 ES R9O, R9NH; R9 ES ALQUILO, CICLOALQUILO; R4 ES H; b) DE 0,1% A 7% DE UNA AMINA TAL COMO ETANOLAMINA, ETILENDIAMINA, TRIS(HIDROXIMETIL)AMINOMETANO; c)ACEITES (TRIGLICERIDOS, VITAMINAS, ACIDOS GRASOS), VEHICULO (POLIMERO, UREA), DISOLVENTES HIDROFILOS (PROPILENGLICOL, ETANOL, AGUA); SI c) ES ACEITE, LA COMPOSICION COMPRENDE ADEMAS d)DISOLVENTES e)HASTA 50% EN PESO DE POLIMEROS COMO POLIETILENGLICOL, POLIVINILPIRROLIDONA, DERIVADOS DE CELULOSA; f)HASTA 70% EN PESO DE TENSIOACTIVOS COMO SUCCINATO DE D-ALFA-TOCOFEROL-POLIETILENGLICOL 1000, ACEITE DE RICINO; SI c) ES UN VEHICULO, LA COMPOSICION COMPRENDE TENSIOACTIVOS. LA COMPOSICION PUEDE COMPRENDER ADEMAS DE 0,01% A 1% DE ANTIOXIDANTES. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35569402P | 2002-02-07 | 2002-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030865A1 true PE20030865A1 (es) | 2003-11-26 |
Family
ID=27734548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000135A PE20030865A1 (es) | 2002-02-07 | 2003-02-05 | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c |
Country Status (25)
Country | Link |
---|---|
US (1) | US6828301B2 (es) |
EP (1) | EP1474172B1 (es) |
JP (1) | JP2005518423A (es) |
KR (1) | KR20040089605A (es) |
CN (1) | CN1627959A (es) |
AR (1) | AR038823A1 (es) |
AT (1) | ATE344056T1 (es) |
AU (1) | AU2003208989A1 (es) |
BR (1) | BR0307524A (es) |
CA (1) | CA2472249A1 (es) |
CO (1) | CO5611167A2 (es) |
DE (1) | DE60309433T2 (es) |
EA (1) | EA200400991A1 (es) |
EC (1) | ECSP045223A (es) |
ES (1) | ES2276045T3 (es) |
HR (1) | HRP20040720A2 (es) |
IL (1) | IL162673A0 (es) |
MX (1) | MXPA04007699A (es) |
NO (1) | NO20043722L (es) |
PE (1) | PE20030865A1 (es) |
PL (1) | PL371287A1 (es) |
TW (1) | TW200302734A (es) |
UY (1) | UY27650A1 (es) |
WO (1) | WO2003066103A1 (es) |
ZA (1) | ZA200405064B (es) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060926A2 (en) | 2000-11-20 | 2002-08-08 | Bristol-Myers Squibb Company | Hepatitis c tripeptide inhibitors |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ES2350201T3 (es) | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c. |
AU2003299519A1 (en) | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1505945B1 (en) | 2002-05-20 | 2008-11-05 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
US20040033959A1 (en) * | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US20040138109A1 (en) * | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
US20050159345A1 (en) * | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
AU2004231538A1 (en) * | 2003-04-02 | 2004-11-04 | Boehringer Ingelheim International, Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
EA200600498A1 (ru) * | 2003-09-22 | 2006-10-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
ES2398912T3 (es) * | 2003-10-14 | 2013-03-22 | F. Hoffmann-La Roche Ltd. | Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2007516239A (ja) | 2003-11-20 | 2007-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特に複分解反応生成物からの、遷移金属の除去方法 |
WO2005070955A1 (en) * | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
SI1713823T1 (sl) | 2004-01-30 | 2010-04-30 | Medivir Ab | Inhibitorji HCV NS-3 serin proteaze |
JP4950026B2 (ja) * | 2004-03-30 | 2012-06-13 | インターミューン・インコーポレーテッド | ウイルス複製阻害剤としての大環状化合物 |
CA2569310A1 (en) * | 2004-06-08 | 2005-12-29 | Maura Murphy | Pharmaceutical compositions |
CA2571984C (en) | 2004-07-16 | 2012-04-10 | Gilead Sciences, Inc. | Antiviral compounds |
WO2007001406A2 (en) * | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
MX2007004783A (es) * | 2004-10-21 | 2007-05-11 | Pfizer | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. |
US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
AU2005302501A1 (en) * | 2004-10-29 | 2006-05-11 | Novartis Ag | Spontaneously dispersible pharmaceutical compositions |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20060240051A1 (en) * | 2005-04-26 | 2006-10-26 | Singleton Andy H | Eutectic blends containing a water soluble vitamin derivative |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1919478B1 (en) * | 2005-06-02 | 2016-03-23 | Merck Sharp & Dohme Corp. | Combination of hcv protease inhibitors with a surfactant |
NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
EP2305696A3 (en) | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
US20090068253A1 (en) * | 2005-09-06 | 2009-03-12 | Guilford F Timothy | Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione |
ES2356776T3 (es) | 2005-10-11 | 2011-04-13 | Intermune, Inc. | Compuestos y métodos para inhibir la replicación del virus de la hepatitis. |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
CN102532198A (zh) * | 2006-07-07 | 2012-07-04 | 吉里德科学公司 | 抗病毒的次膦酸酯化合物 |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2010526834A (ja) * | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規ペプチド阻害剤 |
EA025794B1 (ru) | 2007-06-29 | 2017-01-30 | Джилид Сайэнс, Инк. | Противовирусные соединения |
WO2009005677A2 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8003659B2 (en) | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
EP2282762A2 (en) | 2008-04-15 | 2011-02-16 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN101744823B (zh) * | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
DK2451438T3 (da) * | 2009-07-07 | 2014-03-10 | Boehringer Ingelheim Int | Farmaceutisk sammensætning til en hepatitis C-virus-roteaseinhibitor |
TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
CA2784748A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
WO2011112558A2 (en) * | 2010-03-10 | 2011-09-15 | Abbott Laboratories | Solid compositions |
US9725815B2 (en) | 2010-11-18 | 2017-08-08 | Metalysis Limited | Electrolysis apparatus |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
BR112013016480A2 (pt) | 2010-12-30 | 2016-09-20 | Abbvie Inc | macrocíclo da fenantridina inibadores da protease da serina da hepatite c |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) * | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
RS55592B1 (sr) | 2012-10-19 | 2017-06-30 | Bristol Myers Squibb Co | 9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE445174B (sv) * | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
IL102236A0 (en) * | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
US5376688A (en) * | 1992-12-18 | 1994-12-27 | R. P. Scherer Corporation | Enhanced solubility pharmaceutical solutions |
WO1996036316A1 (en) | 1995-05-19 | 1996-11-21 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
PT989851E (pt) | 1997-07-29 | 2002-12-31 | Upjohn Co | Formulacao auto-emulsionante para compostos lipofilicos acidicos |
RU2203648C2 (ru) * | 1997-07-29 | 2003-05-10 | Фармация Энд Апджон Компани | Самоэмульгирующаяся композиция для липофильных соединений |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
-
2003
- 2003-02-04 US US10/357,919 patent/US6828301B2/en not_active Expired - Lifetime
- 2003-02-05 CA CA002472249A patent/CA2472249A1/en not_active Abandoned
- 2003-02-05 ES ES03707713T patent/ES2276045T3/es not_active Expired - Lifetime
- 2003-02-05 IL IL16267303A patent/IL162673A0/xx unknown
- 2003-02-05 PL PL03371287A patent/PL371287A1/xx not_active Application Discontinuation
- 2003-02-05 MX MXPA04007699A patent/MXPA04007699A/es not_active Application Discontinuation
- 2003-02-05 EP EP03707713A patent/EP1474172B1/en not_active Expired - Lifetime
- 2003-02-05 EA EA200400991A patent/EA200400991A1/ru unknown
- 2003-02-05 UY UY27650A patent/UY27650A1/es not_active Application Discontinuation
- 2003-02-05 AT AT03707713T patent/ATE344056T1/de not_active IP Right Cessation
- 2003-02-05 WO PCT/US2003/003380 patent/WO2003066103A1/en active IP Right Grant
- 2003-02-05 PE PE2003000135A patent/PE20030865A1/es not_active Application Discontinuation
- 2003-02-05 BR BR0307524-9A patent/BR0307524A/pt active Pending
- 2003-02-05 JP JP2003565526A patent/JP2005518423A/ja active Pending
- 2003-02-05 CN CNA03803395XA patent/CN1627959A/zh active Pending
- 2003-02-05 DE DE60309433T patent/DE60309433T2/de not_active Expired - Fee Related
- 2003-02-05 AU AU2003208989A patent/AU2003208989A1/en not_active Abandoned
- 2003-02-05 KR KR10-2004-7012235A patent/KR20040089605A/ko not_active Application Discontinuation
- 2003-02-06 TW TW092102382A patent/TW200302734A/zh unknown
- 2003-02-07 AR ARP030100386A patent/AR038823A1/es not_active Suspension/Interruption
-
2004
- 2004-06-25 ZA ZA200405064A patent/ZA200405064B/en unknown
- 2004-08-06 EC EC2004005223A patent/ECSP045223A/es unknown
- 2004-08-06 HR HR20040720A patent/HRP20040720A2/hr not_active Application Discontinuation
- 2004-09-06 NO NO20043722A patent/NO20043722L/no not_active Application Discontinuation
- 2004-09-07 CO CO04088288A patent/CO5611167A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO5611167A2 (es) | 2006-02-28 |
TW200302734A (en) | 2003-08-16 |
ATE344056T1 (de) | 2006-11-15 |
AR038823A1 (es) | 2005-01-26 |
EP1474172A1 (en) | 2004-11-10 |
DE60309433T2 (de) | 2007-05-03 |
HRP20040720A2 (en) | 2005-04-30 |
NO20043722L (no) | 2004-09-06 |
US20030195228A1 (en) | 2003-10-16 |
UY27650A1 (es) | 2003-09-30 |
BR0307524A (pt) | 2004-12-21 |
EP1474172B1 (en) | 2006-11-02 |
WO2003066103A1 (en) | 2003-08-14 |
ECSP045223A (es) | 2004-09-28 |
AU2003208989A1 (en) | 2003-09-02 |
ES2276045T3 (es) | 2007-06-16 |
ZA200405064B (en) | 2005-05-30 |
KR20040089605A (ko) | 2004-10-21 |
DE60309433D1 (de) | 2006-12-14 |
CA2472249A1 (en) | 2003-08-14 |
EA200400991A1 (ru) | 2005-02-24 |
CN1627959A (zh) | 2005-06-15 |
IL162673A0 (en) | 2005-11-20 |
MXPA04007699A (es) | 2004-11-10 |
US6828301B2 (en) | 2004-12-07 |
JP2005518423A (ja) | 2005-06-23 |
PL371287A1 (en) | 2005-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030865A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR074391A1 (es) | Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral | |
AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
AR026102A1 (es) | Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion | |
ATE409461T1 (de) | Hfc lösungsformulierungen enthaltend ein anticholinergikum | |
AR073760A1 (es) | Derivados heterociclicos y metodos de uso de los mismos | |
DE602004031258D1 (de) | Polycyclische mittel zur behandlung von infektione | |
AR042397A1 (es) | Compuestos de pirazol utiles como inhibidores de proteinquinasa | |
PE20091575A1 (es) | Derivados bifenilo como inhibidores del virus de la hepatitis c | |
PA8494101A1 (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
AR039672A1 (es) | Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat) | |
MX2008001394A (es) | Inhibidores macrociclicos del virus de hepatitis c. | |
UY30493A1 (es) | Compuestos derivados 5-cloro-1??h,3h-espiro[ 1-benzofuran-2, 4??- piperidin]-1??-ilo sustituidos de los acidos acético y 2-metil- propanoico, composiciones farmacéuticas, procedimientos de preparacion y aplicaciones | |
CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
RS49850B (sr) | Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena | |
CR11223A (es) | Compuestos de biciclolactama sustituida | |
CL2004000076A1 (es) | Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi | |
AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
AR032586A1 (es) | Composicion farmaceutica | |
AR054000A1 (es) | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo | |
AR047466A1 (es) | Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles. | |
AR061134A1 (es) | Derivados de tioxantina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |